ProCE Banner Activity

Tumors Deficient in Mismatch Repair Particularly Susceptible to Immune Checkpoint Blockade

Slideset Download
Conference Coverage
Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.

Released: May 31, 2015

Expiration: May 29, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation